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Background. Inﬂammation and remodeling are integral parts of asthma pathophysiology. We sought to describe the clinical and
pathologic features of near fatal asthma exacerbation (NFE). Methods. Bronchial biopsies were collected prospectively from NFE I
subjects. Another NFE II group and a moderate severity exacerbation control group (ME II) were retrospectively identiﬁed—
no biopsies obtained. Results.A l lN F EI I( n = 9) subjects exhibited remodeling and signiﬁcant inﬂammation (eosinophilic,
neutrophilic). NFE II group (n = 37) had a signiﬁcant history of prior intubation and inhaled corticosteroids usage compared
to ME II group (n = 41). They also exhibited leukocytosis, eosinophilia, and longer hospitalization days. Conclusions. Remodeling,
eosinophilic, and neutrophilic inﬂammation were observed in NFE. NFE is associated with prior intubation and inhaled
corticosteroids usage.
1.Introduction
Remodeling in asthma refers to structural changes in
large and small airways, consisting of subepithelial ﬁbrosis,
increased vascularity, increased airway smooth muscle mass,
and goblet cell hyperplasia of proximal and distal airways
[1, 2]. Remodeling was believed originally to be the cause
of refractory asthma, that is, asthma that fails to respond to
optimal treatment and is characterized by persistent airﬂow
limitation [3]. However, apart from severe asthma, bronchial
biopsy studies have shown the features of remodeling in mild
and moderate asthma, as well as in children with asthma and
preschool wheezing [4, 5].
Remodeling and persistent inﬂammation are present in
relatively mild and “benign” asthma, but not many data
exist regarding the pathologic features in severe asthmatic
exacerbations or in near fatal asthma [6]. This study was
conducted in order to characterize the clinical and airway
biopsy features of asthmatic patients who had a near fatal
exacerbation (NFE). The NFE patients are severe asthmatics
whopresentedattheEmergencyDepartment(ED)requiring
admission to the Intensive Care Unit (ICU) and were put
under mechanical ventilation. We hypothesized that this
subgroup of patients was the most likely to exhibit evidence
of airway remodeling.
This observation would particularly help us how to opti-
mally manage these severely compromised patients; studies
in humans but also in animal models yield contradictory
results about the eﬀectiveness of anti-inﬂammatory medi-
cation against remodeling [7, 8]. The clinical phenotypes
associated with an NFE are, as well, of obvious clinical im-
portance.
2.MaterialsandMethods
2.1. Study Design. We deﬁned two subgroups of asthma
subjects who presented with an acute exacerbation at the
ED. One group consisted of severe asthmatics with an NFE
who required intubation and mechanical ventilation and2 Pulmonary Medicine
were admitted to the ICU (NFE group). The second group
consisted of asthma patients with a less severe exacerbation
who were admitted either to the ICU or to a medical
ward and preserved spontaneous breathing. The latter group
responded to conventional therapy and was designated as
themoderateexacerbation(ME)group(controls).Thestudy
c o m p r i s e do fap r o s p e c t i v ea n dar e t r o s p e c t i v ea r m .
2.2. Prospective Arm. Between 2004 and 2009, asthma pa-
tients admitted to Los Angeles County and University of
Southern California (LAC and USC) Medical Center (a pub-
lic university-aﬃliated hospital) and to the USC University
Hospital (USCUH) (a private university-aﬃliated hospital)
with an NFE were included prospectively in the study.
Inclusion criteria were an NFE as deﬁned previously and a
diagnosis of asthma reported by the admitting and the ICU
physician. Exclusion criteria were age below 16th year and
history of Chronic Obstructive Pulmonary Disease (COPD).
Patients underwent bronchoscopy and had mucosal biopsies
of the large proximal airways. These patients comprised NFE
I group. Unfortunately, no ME patients were prospectively
included in the study; as a result, control biopsies were not
available in this study.
2.3. Retrospective Arm. Because of the lack of a prospective
control group, we retrieved in a retrospective fashion the
medical records of adult asthmatics which presented at
the ED and admitted to LAC and USC Medical Center
or to USCUH between 1999 and 2004 with an asthma
exacerbation. As deﬁned previously, they were divided to
those with an NFE (called NFE II group) and those with an
ME(calledMEIIgroup).Nobiopsieswereavailableforthese
retrospectively collected groups. The same inclusion and
exclusioncriteriawiththeprospectivedatawereapplied.The
purpose of the retrospective arm was therefore to provide an
analysis of NFE patients (having similar clinical and social
characteristics with NFE I group) with a control ME group,
unavailable in the prospective arm.
2.4. Baseline Characteristics. We reviewed the charts for
recording of (i) medication used at time of admission
(unfortunately doses of inhalers have not been recorded
at the ED), (ii) smoking habit (in pack/years), and (iii)
respiratory symptoms and signs, blood eosinophilia, and
evidence of infection. Pulmonary function testing was not
recorded in the charts. We believe that the explanation is
twofold: the discomfort of the emergency setting at which
admissions took place and the mainly low socioeconomic
status of most patients which prevented them from regular
and proper follow-up of their disease.
2.5. Institutional Review Board Approval. The study was ap-
proved by the University of Southern California Institutional
Review Board (federal ID number: IRB1 00005904) for the
m e d i c a lc h a r tr e v i e w( r e t r o s p e c t i v eg r o u p )a sw e l la sf o rt h e
patients who underwent bronchoscopy and airway biopsies
(prospective group). Informed consent was obtained from
the patient directly or from the patient’s legal surrogate.
2.6. Bronchoscopy. Bronchoscopy was performed through
the endotracheal tube and mechanical ventilation was per-
formed appropriately and according to the patient’s best
care and management. After each subject was stabilized
with maximum conventional treatment and under sedation,
bronchoscopy was performed at the bedside within 12
hours after intubation (using a Pentax bronchoscope). Five
mucosal biopsies were taken from the right main bronchus,
the bronchus intermedius, and from a lobar bronchus
(middle lobe or upper lobe). The biopsies were superﬁcial in
order to prevent signiﬁcant hemorrhage. Biopsy specimens
were processed in the Pathology Department to be examined
by one pathologist (MK).
2.7. Airway Biopsy Preparation and Processing. The airway
tissues submitted in 10% formalin ﬁxative were embedded
inparaﬃnafterappropriatedehydrationand5-micron-thick
sections cut and stained as follows: one hematoxylin and
eosin-stained slide, one PAS- (periodic acid-schiﬀ-) stained
slide, and one trichrome-stained slide with at least 2 sections
per slide. The numbers of eosinophils, neutrophils, lympho-
cytes, and plasma cells in the highest area of cellularity of
the bronchial wall were scored semiquantitatively as follows:
1–5cells/HPF (high-power ﬁeld) = 1+; 6–10cells/HPF = 2+;
>10cells/HPF = 3+. Next, the respiratory basal lamina was
graded as normal or thickened. The presence of mucinous
and squamous metaplasia was determined by counting
30 contiguous respiratory epithelial cells and noting the
percentage of mucinous or squamous cells among them.
B r o n c h i a lw a l le d e m aw a sj u d g e da sm i l d ,m o d e r a t e ,o r
severe. Finally, to determine the vascularity of the bronchial
wall, the maximum number of capillaries in the airway wall
was counted under a high-power microscopic ﬁeld (×400).
2.8. Statistical Analysis. Values are presented as means ±
standard deviation or frequency and percent. Measured
values between groups NFE II and ME II were analyzed
with two-tailed t test or a nonparametric equivalent (Mann-
Whitney test). χ2 or Fisher’s exact test was performed for
qualitative variables. Relative risk and its 95% conﬁdence
interval were calculated. Correlation analysis was performed
in all groups. A Roc analysis in the retrospective arm was
done to ﬁnd the features with the largest area under the
curve for subsequent intubation. Multiple logistic regression
analysis was also performed to identify independent factors
associatedwithintubationintheretrospectivearm,although
the large number of missing values for some key variables
limited the utility of this approach. The threshold of
statistical signiﬁcance was P<0.05.
3. Results
3.1. Prospective Arm. Patients’ classiﬁcation in groups is
shown in Figure 1. Patients’ demographics are shown in
Table 1 and their clinical characteristics in Table 2.T h e i r
history was remarkable for prior intubation for asthma exac-
erbation (67%) and recent use of systemic corticosteroidsPulmonary Medicine 3
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Figure 1: Flow diagram of study subjects and controls (NFE: near
fatal exacerbation; ME: moderate exacerbation; E: exacerbation;
COPD: chronic obstructive pulmonary disease).
(89%). Only 1 patient (11%) was a smoker. Outcome was
favorable for all 9 patients.
The histopathological ﬁndings of the NFE I subjects are
shown in Table 3. All specimens exhibited increased vascu-
larity, basal lamina thickening, mild to moderate edema,
signiﬁcant inﬂammation, as well as various degrees of mu-
cinous and squamous metaplasia (Figure 2). No airway
smooth muscle cells were retrieved in the specimens, pro-
bably because of the superﬁcially obtained biopsies. Eosino-
phils and lymphocytes were the predominant cells found.
Neutrophils and plasma cells were also increased and, in
some cases, equivalent to the eosinophil population. There
was no signiﬁcant correlation of the biopsy results with the
clinical features or laboratory results.
3.2. Retrospective Arm Analysis. The retrospective arm con-
sisted of groups NFE II and ME II. 2 patients had 2 severe
exacerbations each. Each exacerbation was considered a
separate event (Figure 1). Patients’ demographics are shown
in Table 1. There were missing data for most variables.
ClinicalcharacteristicsofgroupsNFEIIandMEIIareshown
in Table 4. No deaths were recorded in these 2 groups.
The NFE II group exhibited higher heart rate (HR),
respiratory rate (RR), and diastolic blood pressure (DBP).
TheyhadhigherFiO2 administered,higherarterialPO2 and
PCO2, and lower pH than the ME II group. They also had
profound leukocytosis, higher peripheral blood eosinophils
(percentage and absolute counts), as well as longer hospi-
talization days (Mann-Whitney test, P<0.05). In addi-
tion, these patients exhibited higher alveolar-arterial oxygen
Squamous
metaplasia
Basement
membrane
Figure 2: Light microscopic appearance of bronchial biopsy in
asthma (magniﬁcation scale ×400). Features include early squa-
mous metaplasia of bronchial epithelium, thickened respiratory
epithelialbasallamina,andanunderlyingedematousbronchialwall
showing prominent numbers of lymphocytes (purple arrow), some
plasma cells (yellow arrow), and a few eosinophils (red arrows).
gradient (A-aO2) but did not reach statistical signiﬁcance
(P =0.09). Upper respiratory tract infection was common
but not diﬀerent between study subjects and controls.
NFEIIgrouphadasigniﬁcanthistoryofpriorintubation
and prior usage of inhaled corticosteroids comparing to
controls (chi-square test, P<0.05). Doses of corticosteroids
have not been suﬃciently recorded into the charts and
are missing from our study. Multiple logistic regression
conducted with covariates that had no more that 25% miss-
ing data identiﬁed DBP (P =0.0041) and RR (P =0.0024)
as independent clinical risk factors for intubation. The
Roc analysis determined that the length of hospitalization,
absoluteeosinophils,andpercenteosinophiliahadthelarger
area under the curve for intubation (0.89, 0.85, 0.84, resp.).
4. Discussion
Themainoutcomeandtheprimaryhypothesisofthepresent
studyisthat,innearfatalasthmaexacerbators,remodelingof
the proximal airways along with cellular inﬂammation was
commonly observed. To our knowledge, this is the second
study of bronchial biopsies performed in living subjects with
a severe asthma exacerbation, even in a semiquantitative
manner. Although these NFE I patients had a signiﬁcant his-
tory of prior intubation due to asthma and usage of inhaled
and systemically administered corticosteroids, association of
this phenotype with the speciﬁc pathology ﬁndings cannot
be clearly made due to the lack of a biopsied control ME I
group.
Retrospective NFE II subjects in which biopsies were not
performed exhibited leukocytosis, peripheral blood eosino-
philia, and prolonged hospitalization. Independent clinical
risk factors for intubation were higher diastolic blood pres-
sure and greater respiratory rate; however, these results
should be interpreted with caution due to missing data.
These subjects had a signiﬁcant history of prior intubation
and use of inhaled corticosteroids compared to controls.4 Pulmonary Medicine
Table 1: Patients’ demographics. Data are presented as frequency (percent) or as mean ± standard deviation (n).
NFE I group ME II group∗ NFE II group∗
Males 4/9 = 44% 20/41 = 48.8% 17/35 = 48%
Age (years) 48.5 ±15 (9) 48 ±15 (34) 50 ±16 (24)
Race n = 9 n = 39 n = 34
African-American 1 (11.1%) 14 (35.9%) 7 (20.6%)
Caucasian 2 (22.2%) 6 (15.4%) 4 (11.8%)
Hispanic 5 (55.6%) 14 (35.9%) 16 (47%)
Asian 1 (11.1%) 5 (12.8%) 7 (20.6%)
Smoking history 1/9 (11%) 12/28 (43%) 8/26 (31%)
Pack/years 10 ± 3.5( 4 ) 8 .5 ±6( 3 )
Years with asthma 21.5 ±9 (9) 17 ±14 (21) 13 ±9.5 (23)
∗P values between NFE II and ME II groups for age, sex, race, smoking habit, pack/years of smoking, and years with asthma: nonsigniﬁcant.
Table 2:ClinicalcharacteristicsofNFEIgroupattheinitialevalua-
tion. Values are shown as mean ± standard deviation or frequency
and percent.
NFE I (n = 9)
Prior admissions 7 (78%)
Prior intubation 6 (67%)
B2 agonist use 9 (100%)
Inhaled corticosteroids 8 (89%)
Systemic corticosteroids the previous month 8 (89%)
Heart rate (beats/min) 126 ±7
Respiratory rate (breaths/min) 30 ±6
Systolic BP (mmHg) 124 ±21
Diastolic BP (mmHg) 66 ±20
FiO2(%) 59 ±30
PO2 (mmHg) 201 ±137
PCO2 (mmHg) 42 ±16
pH 7.3 ±0.12
A-aO2 (mmHg) 186 ±119
WBC (mm3) 16,286 ±5,580
Eos (%) 0.33 ±0.26
Eos absolute (mm3)5 4 ±50
BUN (mg/dl) 30 ±27
Hospitalization days 7.3 ±4.8
BP: blood pressure; WBC: white blood counts; Eos: eosinophils; A-a:
alveolar-arterial gradient; BUN: blood urea nitrogen.
The major limitation of our study is the lack of a bio-
psied control group (moderate asthma exacerbations). Al-
though they may also exhibit remodeling, our primary goal
was to investigate the pathology of the most severe asth-
ma population. No conclusions can be made regarding the
clinical characteristics associated with remodeling in those
cases, which was the secondary purpose of this study. Retro-
spectively collected NFE II group exhibited, however, very
similar characteristics with NFE I group in terms of age,
race, sex, history, and medication used. They also had a
similar mainly low socioeconomic status as most of them
were underinsured and the study derived from a public
hospital. As a result, we believe that clinical characteristics
of NFE II patients, which are compatible with the currently
known phenotype of Near Fatal Asthma (NFA) (frequent
ED visits, prior intubation), may not be extrapolated to
NFE I patients and therefore associated with remodeling.
Retrospective population provides, however, a very good
reﬂection of the prospective arm of the study.
A second limitation is the lack of pulmonary function
testing and of other missing data (detailed smoking history,
doses of medication). We attribute the former to the poor
monitoring ofasthmathatthesepatientsshowed,anelement
explained in detail here in after. Regarding the latter,
these data have been collected retrospectively from charts
frequently over a decade old and were unable to be retrieved.
A third limitation of our study is the only semiquantitative
description of tissue specimens. We acknowledge that limita-
tion and hope to be addressed in a future study.
Remodeling in near fatal asthma is a reasonable ﬁnding,
along with evidence of acute and chronic inﬂammation.
Epithelial basal lamina thickening, increased smooth muscle
mass, vascularity, and goblet cell hyperplasia are all observed
in various asthma stages (mild, moderate, and severe) [9–
12].Althoughallofourpatientssurvived,itsimpactonshort
term prognosis of an exacerbation was not addressed in this
study and remains to be elucidated.
A major ﬁnding in the tissue specimens of near fatal
asthmatics in our study is the combination of predominant
eosinophilic inﬂammation with remodeling. While eosino-
phils have been associated, as found in our study, with
persistent, severe asthma, their role in the pathogenesis of
remodeling is not so clear. Eosinophils have been shown
to induce remodeling through the production of a strong
ﬁbrogenic cytokine, TGF-β (transforming growth factor-β),
conversion of ﬁbroblasts to myoﬁbroblasts, and excessive
extracellular matrix expression (ECM). Phipps et al. and
Flood-Page and colleagues found that patients with atopic
asthma who received mepolizumab, an anti-IL5 antibody,
exhibited a decrease in lung eosinophilia along with a re-
duction of markers of remodeling, suggesting a close asso-
ciation [13, 14]. Mice models have shown, however, that
remodeling persists after resolution of the inﬂammation [15,
16]. Unfortunately, subsequent biopsies were not obtained
after asthmatic crisis resolution in our study.Pulmonary Medicine 5
Table 3: Pathology ﬁndings of large airways in near fatal asthma exacerbation (NFE I group, n = 9).
S u b j e c t 1 234 5 678 9
Eosinophils 3+ 3+ 3+ 3+ 0+ 1+ 0+ 3+ 1+
N e u t r o p h i l s 1 + 1 +1 +3 + 1 + 1 +1 +3 + 1 +
L y m p h o c y t e s 3 + 3 +3 +3 + 2 + 2 +2 +3 + 3 +
P l a s m a c e l l s 1 + 2 +2 +3 + 1 + 1 +2 +2 + 1 +
Mucinous metaplasia 0% 30% 15% 75% 15% 15% 30% 75% 30%
Squamous metaplasia 100% 20% 30% 50% 10% 20% 30% 20% 50%
Inﬂammation 3+ 3+ 2+ 3+ 1+ 2+ 3+ 3+ 3+
Basal lamina thick thick thick thick thick thick thick thick thick
Edema mild moderate moderate moderate mild moderate moderate moderate mild
Vascularity Vessels/hpf 10+ 10+ 10+ 10+ 10+ 10+ 10+ 9+ 9+
Table 4: Clinical characteristics of NFE II and ME II groups at the initial evaluation. Values are shown as mean ± standard deviation (n)o r
frequency and percent. The relative risk is presented at the last column.
ME II NFE II P Value RR (95% conﬁdence interval)
Prior admissions 19/23 (83%) 22/25 (88%) NS
Prior intubation 9/30 (30%) 16/27 (59%) 0.03 1.97 (1–3.7)
B2 agonist Use 23/25 (92%) 30/33 (91%) NS
Inhaled corticosteroids 6/36 (17%) 16/33 (48%) 0.008 2.9 (1.2–6.5)
Systemic corticosteroids 11/36 (30%) 10/33 (30%) NS
Cough 10/12 (83%) 15/20 (75%) NS
Wheezing 10/12 (83%) 22/23 (96%) NS
Sputum 6/10 (60%) 13/17 (76%) NS
Chest tightness 3/6 (50%) 6/10 (60%) NS
URTI 6/16 (37%) 7/15 (47%) NS
Heart rate (beats/min) 102 ±21 (38) 124 ±20 (35) 0.0001
Respiratory rate (breaths/min) 25 ±6 (38) 32 ±7 (25) <0.0001
Systolic BP (mmHg) 136 ±19 (38) 147 ±39 (36) NS
Diastolic BP (mmHg) 75 ±18 (37) 93 ±25 (34) 0.002
PO2 (mmHg) 85 ±33 (25) 209 ±170 (34) 0.003
PCO2 (mmHg) 41 ±10 (25) 57 ±18 (34) 0.001
pH 7.38 ±0.06 (24) 7.27 ±0.12 (34) 0.0001
FiO2 (%) 40 ±21 (19) 71 ±32 (26) 0.001
A-aO2 (mmHg) 136 ±128 (19) 188 ±142 (26) 0.09
WBC (mm3) 11,500 ±4,000 (29) 15,600 ±6,200 (25) 0.01
Eos (%) 1 ±1.4 (19) 2.75 ±1.5 (4) 0.03
Eos absolute (/mm3) 125 ±198 (19) 445 ±324 (4) 0.03
Hospitalization days 3.8 ±2.6 (27) 9.8 ±5 (7) 0.001
URTI: upper respiratory tract infection; BP: blood pressure; WBC: white blood counts; Eos: eosinophils; A-a: alveolar-arterial gradient; NS: nonsigniﬁcant.
The use of inhaled corticosteroids (CSs) was rather low
in our study subjects (17% in ME II group and 48% in NFE
II group) and signiﬁes nonadherence to current treatment
guidelines [17]. This underlines, to our opinion, the under-
treatment of asthma in the majority of our patients, due
to socioeconomic status and underinsurance. This under-
treatment may be the cause of the peripheral eosinophilia
noticed in the retrospective data. This study could not
address the issue of the eﬀect of CS on remodeling in NFE
biopsied group. Other studies have yielded contradictory
results [18, 19]. Thermoplasty and novel targeted therapies
may prove much more beneﬁcial against remodeling [20,
21]. Another feature of NFE II asthmatics was peripheral
bloodleukocytosis.Possibleexplanationsfortheleukocytosis
might be the use of systemic corticosteroids or an upper
respiratory tract infection (URTI).
Although cases of COPD have been excluded from the
study, a signiﬁcant proportion of study subjects were current6 Pulmonary Medicine
or former smokers. Thus, certain of the study subjects
might have coexistent asthma and COPD or may have been
misdiagnosed as asthma instead of COPD. In the absence of
pulmonary function testing and scheduled posthospitaliza-
tion visit, this issue may not be addressed adequately.
5. Conclusion
In conclusion, this is a descriptive study showing that eosi-
nophilic inﬂammation and remodeling are the predomi-
nant features of near fatal asthma exacerbations. These exac-
erbations are associated with a history of prior endotracheal
intubation and use of inhaled CS. The lack of a moderate
severity exacerbation control group, pulmonary function
testing, and the semiquantitative pathological description is
the limitations of our study.
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